Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies

Open access

Abstract

BACKGROUNDSystemic administration of adeno-associated virus (AAV) can trigger life-threatening inflammatory responses, including thrombotic microangiopathy (TMA), acute kidney injury due to atypical hemolytic uremic syndrome-like complement activation, immune-mediated myocardial inflammation, and hepatic toxicity.METHODSWe describe the kinetics of immune activation following systemic AAV serotype 9 (AAV9) administration in 38 individuals following 2 distinct prophylactic immunomodulation regimens. Group 1 received corticosteroids and Group 2 received rituximab plus sirolimus in addition to steroids to prevent anti-AAV antibody formation.RESULTSGroup 1 participants had a rapid increase in immunoglobulin M (IgM) and IgG. Increase in D-dimer, decline in platelet count, and complement activation are indicative of TMA. All Group 1 participants demonstrated activation of both classical and alternative complement pathways, as indicated by depleted C4 and elevated soluble C5b-9, Ba, and Bb antigens. Group 2 patients did not have a significant change in IgM or IgG and had minimal complement activation.CONCLUSIONSThis study demonstrates that TMA in the setting of AAV gene therapy is antibody dependent (classical pathway) and amplified by the alternative complement pathway. Critical time points and interventions are identified to allow for management of immune-mediated events that impact the safety and efficacy of systemic gene therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci173510

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 IgG and IgM antibodies against AAV9. Group 1 (dashed black lines and solid circles) received an i.v. dose of AAV9 without adjuvant immune modulation regimen (IMR). Group 2 (solid red lines and triangles) received IMR with rituximab and sirolimus before an intravenous dose of AAV9. IMR as an adjunctive therapy to AAV used in Group 2 prevented the formation of IgG and attenuated the formation of IgM. Data shown as mean ± SEM of Group 1 and Group 2 IgG and IgM baseline percentage change. P > 0.05 (nonsignificant), *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Note: The split y axis is used to show the small response in Group2 compared with the 100-fold-higher antibody responses in Group 1.
Figure 1 IgG and IgM antibodies against AAV9. Group 1 (dashed black lines and solid circles) received an i.v. dose of AAV9 without adjuvant immune modulation regimen (IMR). Group 2 (solid red lines and triangles) received IMR with rituximab and sirolimus before an intravenous dose of AAV9. IMR as an adjunctive therapy to AAV used in Group 2 prevented the formation of IgG and attenuated the formation of IgM. Data shown as mean ± SEM of Group 1 and Group 2 IgG and IgM baseline percentage change. P > 0.05 (nonsignificant), *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Note: The split y axis is used to show the small response in Group2 compared with the 100-fold-higher antibody responses in Group 1.CC BY · PubMed Central
Figure 2 Hematology. Figure shows the percentage change from baseline for platelet count and D-dimer for Group 1 (dashed black lines and solid circles) and Group 2 (solid red lines and triangles). The data suggest that IMR as an adjunctive therapy to AAV used in Group 2 limits the depletion of platelets and the increase in D-dimer after AAV infusion. Data shown as mean ± SEM of Group 1 and Group 2 baseline percentage change for hematology. P > 0.05 (nonsignificant), *P ≤ 0.05, **P ≤ 0.01.
Figure 2 Hematology. Figure shows the percentage change from baseline for platelet count and D-dimer for Group 1 (dashed black lines and solid circles) and Group 2 (solid red lines and triangles). The data suggest that IMR as an adjunctive therapy to AAV used in Group 2 limits the depletion of platelets and the increase in D-dimer after AAV infusion. Data shown as mean ± SEM of Group 1 and Group 2 baseline percentage change for hematology. P > 0.05 (nonsignificant), *P ≤ 0.05, **P ≤ 0.01.CC BY · PubMed Central
Figure 3 Complement system markers. Figure shows C3, C4, C3a, C4a, Ba, Bb, C5a, and SC5b-9 for Group 1 (dashed black lines and solid circles) and Group 2 (solid red lines and triangles). Participants in Group 1 presented with activation of the complement system, as demonstrated by a reduction in C3 and C4, as well as increased C3a, C4, C5a, Ba, Bb, and SC5b-9. The activation of Ba and Bb indicates that both classical and alternative pathway are involved. On the other hand, Group 2 did not show an activation of the complement system, suggesting that IMR as an adjunctive therapy to AAV prevents the activation of the complement system. Data shown as mean ± SEM of Group 1 and Group 2 baseline percentage change for complement. P > 0.05 (nonsignificant), *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
Figure 3 Complement system markers. Figure shows C3, C4, C3a, C4a, Ba, Bb, C5a, and SC5b-9 for Group 1 (dashed black lines and solid circles) and Group 2 (solid red lines and triangles). Participants in Group 1 presented with activation of the complement system, as demonstrated by a reduction in C3 and C4, as well as increased C3a, C4, C5a, Ba, Bb, and SC5b-9. The activation of Ba and Bb indicates that both classical and alternative pathway are involved. On the other hand, Group 2 did not show an activation of the complement system, suggesting that IMR as an adjunctive therapy to AAV prevents the activation of the complement system. Data shown as mean ± SEM of Group 1 and Group 2 baseline percentage change for complement. P > 0.05 (nonsignificant), *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.CC BY · PubMed Central
Figure 4 Peripheral blood smear. Sequence of peripheral blood smears after gene therapy administration in patient samples revealing increased schistocytes (blue circles), demonstrating evidence of endothelial damage, burr cells, polychromatic red blood cells, and thrombocytopenia, suggesting thrombotic microangiopathy. Blood smear of a patient with DMD (Group 1B) who received the investigational drug product in NCT03368742.
Figure 4 Peripheral blood smear. Sequence of peripheral blood smears after gene therapy administration in patient samples revealing increased schistocytes (blue circles), demonstrating evidence of endothelial damage, burr cells, polychromatic red blood cells, and thrombocytopenia, suggesting thrombotic microangiopathy. Blood smear of a patient with DMD (Group 1B) who received the investigational drug product in NCT03368742.CC BY · PubMed Central
Figure 5 Immunological event timeline. Events: (1) AAV dosing and capsid biodistribution; (2) platelet, C3, and C4 depletion; (3) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevation; (4) D-dimer elevation; (5) IgM elevation; (6) SC5b-9, C5a, C3a, and C4a elevation; (7) Bb, Ba, and factor I elevation; and (8) IgG elevation. The curve for each parameter was created using the average values obtained in the corticosteroid monotherapy group. The curves of each parameter were overlaid on the graph to show the peaks and trough over time, creating a timeline of events. The amplitude of each curve was adjusted to fit all the curves in 1 graph. The ratio of the peaks’ amplitude was maintained from the original data.
Figure 5 Immunological event timeline. Events: (1) AAV dosing and capsid biodistribution; (2) platelet, C3, and C4 depletion; (3) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevation; (4) D-dimer elevation; (5) IgM elevation; (6) SC5b-9, C5a, C3a, and C4a elevation; (7) Bb, Ba, and factor I elevation; and (8) IgG elevation. The curve for each parameter was created using the average values obtained in the corticosteroid monotherapy group. The curves of each parameter were overlaid on the graph to show the peaks and trough over time, creating a timeline of events. The amplitude of each curve was adjusted to fit all the curves in 1 graph. The ratio of the peaks’ amplitude was maintained from the original data.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Research works printed but not linked: 2

  1. Solid Biosciences. Solid Biosciences Provides SGT-001 Program Update. https://www.solidbio.com/about/media/press-releases/solid-biosciences-provides-sgt-001-program-update Updated November 12, 2019. Accessed November 1, 2023
  2. Pfizer. Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (dmd) Support Advancement into Pivotal Phase 3. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-new-phase-1b-results-gene-therapy-ambulatory-boys Updated May 15, 2020. Accessed November 2, 2023

Cited by

See all 163

Metadata

Authors
Salabarria, S. M., Corti, M., Coleman, K. E., Wichman, M. B., Berthy, J. A., D’Souza, P., Tifft, C. J., Herzog, R. W., Elder, M. E., Shoemaker, L. R., Leon-Astudillo, C., Tavakkoli, F., Kirn, D. H., Schwartz, J. D., & Byrne, B. J.
Affiliations
  • University of Florida Health (US)
  • National Institutes of Health (US)
  • Indiana University South Bend (US)
Corresponding author
Byrne, Barry J.
Venue
Journal of Clinical Investigation
Published
2024-01-02
Volume
134
Issue
1
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4388860142
Cited by
159
References
35
Citations by year
2026: 59 · 2025: 55 · 2024: 44
FWCI
26.36
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
College of Medicine, University of Florida (HD052682)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
thrombotic microangiopathy, AAV9, AAV gene therapy, complement activation, classical complement pathway, alternative complement pathway, rituximab, rapamycin, corticosteroids, immunomodulation, D-dimer, atypical hemolytic uremic syndrome, immune-mediated toxicity
MeSH terms
Dependovirus, Humans, Immunoglobulin G, Immunoglobulin M, Thrombotic Microangiopathies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies. https://app.cochat.ai/papers/10.1172/jci173510
The paper
Salabarria, S. M., Corti, M., Coleman, K. E., Wichman, M. B., Berthy, J. A., D’Souza, P., Tifft, C. J., Herzog, R. W., Elder, M. E., Shoemaker, L. R., Leon-Astudillo, C., Tavakkoli, F., Kirn, D. H., Schwartz, J. D., & Byrne, B. J. (2024). Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies. Journal of Clinical Investigation. https://doi.org/10.1172/jci173510

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.